mTOR Cancer Research Results

mTOR, mammalian target of rapamycin: Click to Expand ⟱
Source: HalifaxProj (inhibit)
Type:
mTOR (mechanistic target of rapamycin) is a central regulator of cell growth, proliferation, metabolism, and survival. It is a serine/threonine kinase that integrates signals from nutrients, growth factors, and cellular energy status.
mTOR promotes protein synthesis and cell growth by activating downstream targets such as S6 kinase and 4E-BP1. In cancer, this pathway can become hyperactivated, leading to uncontrolled cell proliferation.

mTor Inhibitors:
-rapamycin (Sirolimus): classic natural product mTOR inhibitor
-Curcumin
-Resveratrol
-Epigallocatechin Gallate (EGCG)
-Honokiol
PC, Pancreatic Cancer: Click to Expand ⟱
Pancreatic Cancer: Hypoxia (low oxygen tension) is commonly found in solid tumors. Hypoxia-inducible factor-1 (HIF-1),is a key mediator of the cellular response to hypoxia and is overexpressed in a wide variety of solid tumors, including pancreatic cancer.
Nanog is highly expressed in CSCs compared to normal cells [93–97]
HIF-1↑
Scientific Papers found: Click to Expand⟱
1580- Citrate,    Citrate activates autophagic death of prostate cancer cells via downregulation CaMKII/AKT/mTOR pathway
- in-vitro, Pca, PC3 - in-vivo, PC, NA - in-vitro, Pca, LNCaP - in-vitro, Pca, WPMY-1
Apoptosis↑, Ca+2↓, Akt↓, mTOR↓, selectivity↑, TumCP↓, cl‑Casp3↑, cl‑PARP↑, LC3‑Ⅱ/LC3‑Ⅰ↑, p62↓, ATG5↑, ATG7↑, Beclin-1↑, TumAuto↑, CaMKII ↓,
476- CUR,    The effects of curcumin on proliferation, apoptosis, invasion, and NEDD4 expression in pancreatic cancer
- in-vitro, PC, PATU-8988 - in-vitro, PC, PANC1
TumCMig↓, TumCI↓, Apoptosis↑, NEDD9↓, p‑Akt↓, p‑mTOR↓, PTEN↑, p73↑, β-TRCP↑,
19- Deg,    Deguelin inhibits proliferation and migration of human pancreatic cancer cells in vitro targeting hedgehog pathway
- in-vitro, PC, Bxpc-3 - in-vitro, PC, PANC1
HH↓, Gli1↓, PTCH1↓, Sufu↓, MMP2↓, MMP9↓, PI3K/Akt↓, HIF-1↓, VEGF↓, IKKα↓, NF-kB↓, EMT↓, AMPK↑, mTOR↓, survivin↓, TumCG↓, Apoptosis↑, TumCMig↓, TumCI↓,
4853- Uro,    Urolithin A, a novel natural compound to target PI3K/AKT/mTOR pathway in pancreatic cancer
- vitro+vivo, PC, MIA PaCa-2 - in-vitro, NA, PANC1
p‑Akt↓, p‑p70S6↓, TumCG↓, OS↑, PI3K↓, mTOR↓, TumCP↓, TumCMig↓, Apoptosis↑, TAMS↓, Treg lymp↓, Wnt↓, IGF-1↓, *toxicity↓, *BioAv↑, Half-Life↝,

Showing Research Papers: 1 to 4 of 4

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 4

Pathway results for Effect on Cancer / Diseased Cells:


Core Metabolism/Glycolysis ⓘ

AMPK↑, 1,   ATG7↑, 1,   PI3K/Akt↓, 1,  

Cell Death ⓘ

Akt↓, 1,   p‑Akt↓, 2,   Apoptosis↑, 4,   cl‑Casp3↑, 1,   survivin↓, 1,   β-TRCP↑, 1,  

Kinase & Signal Transduction ⓘ

CaMKII ↓, 1,   p‑p70S6↓, 1,  

Autophagy & Lysosomes ⓘ

ATG5↑, 1,   Beclin-1↑, 1,   LC3‑Ⅱ/LC3‑Ⅰ↑, 1,   p62↓, 1,   TumAuto↑, 1,  

DNA Damage & Repair ⓘ

p73↑, 1,   cl‑PARP↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

EMT↓, 1,   Gli1↓, 1,   HH↓, 1,   IGF-1↓, 1,   mTOR↓, 3,   p‑mTOR↓, 1,   PI3K↓, 1,   PTCH1↓, 1,   PTEN↑, 1,   Sufu↓, 1,   TumCG↓, 2,   Wnt↓, 1,  

Migration ⓘ

Ca+2↓, 1,   MMP2↓, 1,   MMP9↓, 1,   NEDD9↓, 1,   Treg lymp↓, 1,   TumCI↓, 2,   TumCMig↓, 3,   TumCP↓, 2,  

Angiogenesis & Vasculature ⓘ

HIF-1↓, 1,   TAMS↓, 1,   VEGF↓, 1,  

Immune & Inflammatory Signaling ⓘ

IKKα↓, 1,   NF-kB↓, 1,  

Drug Metabolism & Resistance ⓘ

Half-Life↝, 1,   selectivity↑, 1,  

Functional Outcomes ⓘ

OS↑, 1,  
Total Targets: 46

Pathway results for Effect on Normal Cells:


Drug Metabolism & Resistance ⓘ

BioAv↑, 1,  

Functional Outcomes ⓘ

toxicity↓, 1,  
Total Targets: 2

Scientific Paper Hit Count for: mTOR, mammalian target of rapamycin
1 Citric Acid
1 Curcumin
1 Deguelin
1 Urolithin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:21  Cells:%  prod#:%  Target#:209  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page